BioSpace News Archive

AlzeCure Pharma AB announced that its Year-end report for 2021 is now available on the company’s website.

The demand for Elekta’s solutions continued to be strong in the third quarter, the fifth consecutive quarter with underlying order growth, resulting in Elekta’s strongest order backlog ever.

Atamyo Therapeutics, a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular diseases, announced multiple major regulatory and financial milestones for ATA-100, a one-time gene therapy for the treatment of fukutin-related protein limb-girdle muscular dystrophy Type 2I/R9.

COPENHAGEN, Denmark; February 24, 2022 – Genmab A/S summons the Annual General Meeting on Tuesday, March 29, 2022, at 2:00 PM CEST at the Copenhagen Marriott Hotel, KalvebodBrygge 5, DK-1560 Copenhagen V, Denmark.

MannKind Corporation was informed that the U.S. Food and Drug Administration issued an information request to United Therapeutics Corporation earlier this month regarding the New Drug Application for Tyvaso DPI, requesting additional information regarding the pulmonary safety of Tyvaso DPI related to a pending Citizen Petition.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the second quarter ended December 31, 2021.

Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the fourth quarter ended December 31, 2021.

Eagle Pharmaceuticals, Inc. today announced that the Company will release its 2021 fourth quarter and full year financial results on Monday, March 7, 2022, before the market opens.

Immuneering Corporation today announced that management will participate in two March investor conferences to share commentary around the Company’s pipeline, platform, and business strategy.

AdaptHealth Corp. announced today financial results for the fourth quarter and fiscal year ended December 31, 2021.